Research analysts at Jefferies Financial Group initiated coverage on shares of ADMA Biologics (NASDAQ:ADMA) in a research report issued to clients and investors on Tuesday, BenzingaRatingsTable reports. The firm set a “buy” rating and a $8.00 price target on the biotechnology company’s stock. Jefferies Financial Group’s price objective indicates a potential upside of 90.48% from the stock’s current price.

ADMA has been the topic of a number of other research reports. WBB Securities upgraded ADMA Biologics to a “buy” rating in a report on Thursday, April 4th. HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of ADMA Biologics in a report on Thursday, February 7th. Oppenheimer raised their target price on ADMA Biologics from $14.00 to $16.00 and gave the company an “outperform” rating in a report on Tuesday, April 2nd. Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy” rating in a report on Thursday, February 14th. Finally, ValuEngine upgraded ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Ten equities research analysts have rated the stock with a buy rating, The stock currently has a consensus rating of “Buy” and an average price target of $10.93.

Shares of NASDAQ:ADMA opened at $4.20 on Tuesday. The company has a market capitalization of $239.05 million, a price-to-earnings ratio of -2.90 and a beta of 2.92. The company has a debt-to-equity ratio of 5.70, a quick ratio of 2.39 and a current ratio of 4.60. ADMA Biologics has a 52-week low of $2.08 and a 52-week high of $6.96.

ADMA Biologics (NASDAQ:ADMA) last posted its earnings results on Wednesday, March 13th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.33) by ($0.06). ADMA Biologics had a negative net margin of 370.27% and a negative return on equity of 210.69%. The company had revenue of $4.06 million during the quarter, compared to the consensus estimate of $5.19 million. Equities research analysts anticipate that ADMA Biologics will post -1.16 earnings per share for the current year.

In other ADMA Biologics news, Director Lawrence P. Guiheen purchased 25,000 shares of the company’s stock in a transaction that occurred on Friday, May 17th. The shares were acquired at an average cost of $4.00 per share, for a total transaction of $100,000.00. Following the completion of the acquisition, the director now owns 50,000 shares of the company’s stock, valued at approximately $200,000. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Life Sciences Maste Perceptive purchased 4,000,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 21st. The shares were acquired at an average price of $4.00 per share, for a total transaction of $16,000,000.00. The disclosure for this purchase can be found here. Insiders bought 4,064,500 shares of company stock worth $16,258,000 in the last 90 days. Corporate insiders own 16.90% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. United Services Automobile Association bought a new stake in ADMA Biologics during the fourth quarter worth $27,000. Dimensional Fund Advisors LP bought a new stake in ADMA Biologics during the fourth quarter worth $34,000. Burns J W & Co. Inc. NY bought a new stake in ADMA Biologics during the first quarter worth $55,000. Rhumbline Advisers lifted its holdings in ADMA Biologics by 50.5% during the fourth quarter. Rhumbline Advisers now owns 23,279 shares of the biotechnology company’s stock worth $56,000 after acquiring an additional 7,810 shares during the period. Finally, ExodusPoint Capital Management LP bought a new stake in ADMA Biologics during the first quarter worth $59,000. Institutional investors and hedge funds own 48.49% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.

See Also: Terms to Better Understand Call Options

Analyst Recommendations for ADMA Biologics (NASDAQ:ADMA)

Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.